The market for cell banking is expanding rapidly, with a global estimate market of $5 billion USD in 2022. However, according to new research from DataM Intelligence, the market is expanding at a 15.68% compound annual growth rate and is expected to hit an estimate valuation of $15.9 billion USD by 2031.
According to its report, “The Stem Cell Banking market focuses on the collection, processing, and storage of stem cells from sources like umbilical cord blood, bone marrow, and adipose tissue for future medical use. Rising awareness of regenerative medicine, advancements in stem cell therapies, and increasing prevalence of chronic diseases are driving market growth globally.”
What makes this market so exciting for companies like CytoMed Therapeutics (NASDAQ: GDTC), outside its remarkable CAGR, is the utility of umbilical cord blood.
As noted in a review article by The National Library of Medicine, “While cord blood is primarily utilized in allogeneic hematopoietic cell transplantation, the development of novel cell therapy products from cord blood is a growing and developing field.
“Compared to adult blood, cord blood is characterized by a higher percentage of hematopoietic stem cells and progenitor cells, less mature immune cells that retain a high capacity of proliferation, and stronger immune tolerance that requires less stringent HLA-matching when used in the allogenic setting.
“… cord blood lends itself as a readily available and safe starting material for the development of off-the-shelf cell therapies. Moreover, non-hematologic cells… also have potential in regenerative medicine and inflammatory and autoimmune conditions.”
For these reasons, among others, CytoMed Therapeutics, through its subsidiary IPSC Depository, recently acquired certain assets of Malaysian cord blood bank, Cellsafe International.
Evelyn Tan, IPSC Depository CEO said, “This acquisition seeks to unlock the therapeutic potential of umbilical cord blood and adds a new strategic dimension targeting longevity and wellness.
“While CytoMed, our publicly listed holding company, will continue to focus on cancer therapeutics, our new subsidiary, LongevityBank will focus exclusively on the regenerative medicine market, with its ultimate goal to be potentially spun off in the future.”
Research from SNS Insider shows the Regenerative Medicine Market is projected to be valued at $235.98 billion by 2032. By obtaining and growing a foothold in this particular segment, CytoMed Therapeutics, through its subsidiaries, looks to grow not only its market shares, but also to diversify its overall product offerings in the health and wellness space.
Read the DataM Intelligence report on the stem cell banking market, HERE
Or see the latest press releases from CytoMed Therapeutics (NASDAQ: GDTC), HERE
On August 30, 2017, the US Food and Drug Administration approved the very first Chimeric Antigen Receptor T-cell therapy (CAR T-cell), tisagenlecleucel (KymriahTM), for treatment of pediatric and young adult Acute Lymphoblastic Leukemia. Eight years subsequently, we have witnessed tremendous advancements of immunotherapy in basic research and their breakthrough into clinical trials.
This is evident from the observation that seven CAR T-cell based cancer therapies were approved in the US in 2024 alone. Furthermore, there are over 1,000 clinical trials ongoing worldwide, in various stages, exploring this exciting technology for the treatment of diverse tumor types.
Mary McGann, PharmD, BCOP – a clinical pharmacy specialist in bone marrow transplant and cellular therapy – told Pharmacy Practice News, it’s “Definitely an exciting time. I feel like every year we almost double the number of CAR-T patients that we have.”
With the FDA having approved an additional six CAR T-cell treatments for use in qualified patients to date, the global market for CAR T-cell therapies is expected to reach at least $27 billion by 2033.
Amongst the companies participating in clinical trials right now, Cytomed Therapeutics (NASDAQ: GDTC) is exploring the use of its products as an “off-the-shelf” allogeneic cellular immunotherapy to be used for a broad spectrum of cancers.
Unlike most CAR T-cell therapies, CytoMed’s products aim to use healthy donor cells, rather than cells from compromised patients, to engineer the therapy by developing a single allogeneic product for the treatment of a wide array of cancers.
The company has an ongoing clinical trial currently in Singapore, with and an upcoming trial in India.
Cytomed Therapeutics’ Chairman, Peter Choo, said of the global increase in clinical trials and FDA approvals, “The science behind CAR T-cell therapies has shown to be a real-life saver. It is exciting to see the US FDA finally taking notice of its promise.
“While we are currently involved in two separate trials, we do believe this year, 2025, could very well prove to be the year where we, and the industry as a whole, are proven to not only be viable, but essential in the global fight against cancer.
“Further, our products, as a differentiator, look to treat a multitude of tumors, both solid and liquid, via commercial production, and to do so at a much lower cost than current therapies.
“By achieving this, we believe we could open up treatment for far more patients, with hopes of saving far more lives.”
With the large number of CAR T-cell therapies currently in clinical trials, the outlook for 2025 is very bright. However, the average cost per patient for CAR T-cell therapy in the United States often exceeds $400,000.
The key to real success, outside of patient remission, will be, as Mr. Choo believes, bringing the cost of CAR T-cell therapies down significantly, which is CytoMed’s core approach with its technology.
Read more about CytoMed Therapeutics’ pipeline, HERE
It’s been about 18 years since a four year girl diagnosed with neuroblastoma (a solid tumor cancer) received her first CAR T-cell therapy in clinical trial. Now in her 20’s, she’s been cancer-free for nearly two decades, one of the longest reported remissions following this breakthrough therapy.
However, while tens of thousands of patients have been treated to date with CAR T-cell therapies worldwide, many with great success, this particular case stands as a testament to science, and most importantly, where it is headed.
You see, the vast majority of CAR T-cell recipients are treated for hematological or blood cancers, as solid tumors like neuroblastoma have been, thus far, difficult to effectively target. Unfortunately for most of the patients in the trial cited above, the results were mixed.
Of the 19 children treated with CAR T-cell therapy (all diagnosed with neuroblastoma), 12 unfortunately died within seven years of treatment, and five were disease free after 10-15 years, with one patient (the young lady mentioned above) still in remission.
But a new clinical trial is soon taking place in India, with the ultimate objective to make cell therapy accessible to more patients.
CytoMed Therapeutics (NASDAQ: GDTC) in collaboration with SunAct Cancer Institute, has entered a Phase 1/Phase 2 clinical trial using CytoMed’s proprietary allogeneic gamma delta T cells for treating various cancers, including solid tumors.
Peter Choo, Chairman of CytoMed Therapeutics said, “CytoMed’s collaboration with SunAct is timely and complements our core focus of harnessing CytoMed’s proprietary off-the-shelf technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers at affordable cost.
“We are aligned with the foresight of our partner SunAct to provide affordable no-option cancer therapeutics that could improve patients’ quality of life.”
Ultimately, should the trial prove successful, the company hopes to increase remission rates for solid tumor patients, while creating a CAR T-cell therapy that is far more affordable, wide ranging and accessible.
To read more about the CytoMed/SunAct collaboration, visit HERE
Or, to read more about the young lady who is nearing the two decade mark in remission, visit HERE
New research from SNS Insider shows the Regenerative Medicine Market is projected to be valued at $235.98 billion by 2032. Notably, the firm says the market, valued at $32.50 billion in 2023, is experiencing significant growth due to new, innovative therapies for chronic disease and advances in stem cell technology.
These new and innovative therapies look to target chronic disease, cancer, genetic disorders and degenerative conditions.
“In 2023, cell therapy held the dominant share of the regenerative medicine market, accounting for 35% of the total market share. This segment is experiencing robust growth due to its broad applicability in various therapeutic areas such as oncology, musculoskeletal disorders, and neurological diseases.
“The introduction of innovative treatments like CAR-T cell therapy has dramatically advanced the efficacy of cancer therapies, particularly in treating blood cancers such as leukemia and lymphoma,” an excerpt from the report shows.
Of the new research, Peter Choo, Chairman of CytoMed Therapeutics (NASDAQ: GDTC) said, “The prevalence of both chronic, degenerative disease and cancer is, unfortunately on the rise due to an aging world. I agree with SNS’s assessment of the 2032 market value for therapeutics targeting these conditions.
“I would add, however, CytoMed is right now working on CAR T-cell therapies that that target solid cancers. Not only blood cancers like leukemia and lymphoma as the report notes, but an entire host of solid tumors as well.
“For this reason, and of course to assist patients of cancer and degenerative diseases, CytoMed Therapeutics has not only concentrated its efforts on its advanced, off-the-shelf allogenic CAR T-cell cancer therapies, but has acquired the valued assets of cord blood bank CellSafe International.
“This acquisition gives us direct access to rare precious cord blood. Naïve cord blood offers a wide range of opportunities in the fields of regenerative medicine and aging diseases, including auto-immune diseases.
“Further, we were able to acquire CellSafe’s assets at a very reasonable cost. These resources, combined with our scientific expertise, may allow the company to introduce advanced cell technology products into the fast-growing regenerative medicine market,” he said.
For more information on CytoMed Therapeutics and its acquisition of Cord Blood Bank, CellSafe International, visit HERE
Or, to access to the SRS report on Regenerative Medicine, visit HERE